The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | CD19 CAR-T for CNS lymphoma
Tanya Siddiqi, MD, City of Hope, Duarte, CA, discusses an ongoing phase I trial (NCT02153580) investigating an autologous CD19-specific, hinge-optimized, CD28 costimulatory CAR-T product for the treatment of relapsed/refractory B-cell non-Hodgkin lymphomas (NHL), including CNS lymphoma. Thus far, early results appear promising in patients with primary and secondary CNS lymphoma – a group with great unmet clinical need. Expansion phase enrollment is continuing and the group also plan to explore an intraventricular route of CAR-T delivery. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
